Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience

Oncology

Volumn 56, Issue 1, 1999, Pages 1-12

  Kollmannsberger, C ^a   Mross, K ^b   Jakob, A ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b University of Tübingen ^*

Author keywords

Pase I studies; Pharmacology; Topoisomerase I inhibition; Topotecan

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; LACTONE; PACLITAXEL; TOPOTECAN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DNA REPLICATION; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INFUSION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG UPTAKE; FATIGUE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LEUKEMIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SARCOMA; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0032922740     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011923     Document Type: Review

References (99)

1. Wall ME, Wami MC, Cook CE, Palmer KH, McPhail AT, Sim GA: Plant antitumor agents. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca accuminata. J Am Chem Soc 1966;88:3888-3890.
2. Burris HA III, Fields SM: Topoisomerase I inhibitors: An overview of the camptothecin analogs. Hematol Oncol Clin North Am 1994; 8:333-355.
3. Moertel CG, Schutt AJ, Reitmeier RJ, Hahn RG: Phase II study of topotecan (NSC-100880) in the threatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-101.
4. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS: Phase I clinical trial of weekly and daily treatment with topotecan (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-521.
5. Hsiang YH, Hertzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878.
6. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by topotecan. Cancer Res 1989;49: 5077-5087.
7. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug topotecan. Cancer Res 1985;48:1722-1726.
8. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y: Structure-activity study of the actions of topotecan derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989;49:1465-1469.
9. Herben VM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102.
10. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 1994;20:73-96.
11. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug topotecan. Cancer Res 1988;48:1722-1726.
12. DelBino G, Lassota P, Darzynkiewicz Z: The S-phase cytotoxicity of topotecan. Exp Cell Res 1991;193:27-35.
13. Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F: Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies. Clin Cancer Res 1997;3:955-961.
14. von Hoff DD, Burris HA III, Eckardt J, Rothenberg M, Fields SM, Chen S-F, Kuhn J: Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994;34:41-45.
15. Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, Rosing H, Hansen HH: Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-678.
16. Mross K, Unger C: Topotecan: Topoisomerase-I-Inhibitor mit breiter Antitumorwirksamkeit. Arzneimitteltherapie 1997;6:171-178.
17. Carmichael J, Ozols RF: Topotecan, an active new antineoplastic agent: Review and current status. Exp Opin Invest Drugs 1997;6:593-608.
18. Schellens JHM, Creemers G, Beijnen JH: Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor. Br J Cancer 1996;73:1268-1271.
19. Kuhn J, Rizzo J, Eckhardt J, Fields S, Cobb P, Rodriquez G, Rinadi D, Drengler R, Smith L, Peacock N, Thurman A, DeLaCruz P, Hodges S, Von Hoff D, Burris H: Phase I bioavailability study of oral topotecan (abstract 1538). Proc ASCO 1995;14:474.
20. O'Dwyer P, LaCreta F, Haas N, Halbherr T, Frucht H, Goosenberg E, Yao K-S: Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994; 34:46-52.
21. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Von Hoff D, Garteiz D, Raber M: Phase I trial of topotecan administered by a 24-hr-infusion (abstract). Proc AACR 1991;32: 1229.
22. Wall JG, Burris HA III, von Hoff DD, Rodriguez G, Kneuper HR, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-345.
23. Grochow L, Slichenmayer W, Rowinsky E, Donehower R, Forastiere A, Chen T-L: Phase I clinical and pharmacological study of topotecan (TOP) in patients with hepatic or renal dysfunction. Ann Oncol 1994;5(suppl 5):191.
24. O'Reilly S, Rowinsky E, Slichenmyer W: Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-3073.
25. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower R, Forastiere A, Ettinger D, Chen T-L, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow L: Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996;88:817-824.
26. Van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, Meas RA, Beijnen JH: Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every three weeks. Cancer Chemother Pharmacol 1995;35:237-245.
27. Hochster H, Liebes A, Jacquotte Z, Sorich J, Speyer J, Oratz R, Chachoua A, Blum R, Taubes B, Ludwig E, Kim A, Fry D, Broom C, Potmesil M: Pharmacodynamics of 21 day topotecan infusion in a phase II study of ovarian cancer: Correlation with TPT administration and heme toxicity (abstract 1507). Proc ASCO 1996;15:476.
28. Rowinsky E, Grochow L, Hendricks C, Ettinger D, Forstiere A, Hurowitz L, McGuire W, Sartorius S, Lubejko B, Kaufmann S, Donehower R. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-656.
29. Saltz L, Sirott M, Young Ch, Tong W, Niedzwiecki D, Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-1507.
30. Burris H, Hanauske A, Johnson R, Marshall M, Kuhn J, Hilsenbeck S, van Hoff D: Activity of topotecan, a new topoisomerase I inhibitor against human tumor coloncy forming units in vitro. J Natl Cancer Inst 1992;23:1816-1820.
31. Houghton P, Chesire P, Hallman J, Lutz L, Friedman H, Danks M, Houghton J: Efficacy of topoisomerase I inhibitor topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
32. Gerrits C, de Jonge M, Schellens J, Stoter G, Verweji J: Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 1997;76:952-962.
33. Abbruzzesse J, Madden T, Schmidt S, Eaton G, Raber M: Phase I trial of topotecan (TT) administered by 24-hour-infusion without and with G-CSF. Proc AACR 1993;34:329.
34. Haas N, LaCreta F, Walczak J, Hudes G, Brennan J, Ozols R. O'Dwayer P: Phase I/II pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54:1220-1226.
35. Burris H III, Awada A, Kuhn J: Phase I and pharmacokinetic study of topotecan administered as a 72 or 120h continuous infusion. Anticancer Drugs 1994;5:394-402.
36. Sabiers J, Berger N, Berger S, Haaga JR, Hoppel CR, Willson JKV: Phase I trial of topotecan administered as a 72 hour infusion. Proc Am Assoc Cancer Res 1993;34:426.
37. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci R, Blum R: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 1994;12:553-559.
38. Hochster H, Liebes L, Zeleniuch-Jacquotte A, Speyer J, Oratz R, Wernz J, Sorich J, Taubes B, Vinci R, Kim A, Fry D, Blum R, Potmesil M: Progressive cleavable complex (CC) formation with 21 day topotecan infusion: A phase I pharmacodynamic study (abstract 1496). Proc Am Soc Clin Oncol 1995;14:463.
39. Rowinsky E, Adjei A, Donehower R, Gore S, Jones R, Burke P, Cheng Y-C, Grochow L, Kaufmann S: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994;12:2193-2203.
40. Seiter K, Feldmann E, Dorota Halicka H, Traganos F, Darzynkiewicz Z, Lake D, Ahmed T: Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J Clin Oncol 1997;15:44-51.
41. Rowinsky E, Grochow L, Sartorius S, Bowling M, Kaufmann S, Peereboom D, Donehower R: Phase I and pharmacologic study of high-doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14: 1224-1235.
42. Gerrits C, Burris H, Schellens J, Planting A, van Burg M, Loos W, Broom C, Hudson I, Verweij J, van Hoff D: 5 days of once daily oral topotecan, a phase I and pharmacologic study in adults (abstract 5910). Ann Oncol 1996; 7(suppl 5):124.
43. Burris H, Gerrits C, Schellens J, Eckhardt J, van Burg M, Planting A, Broom C, Hudson I, von Hoff D, Verweij J: Oral topotecan for 10 days once daily and twice daily every 3 weeks: A phase I and pharmacologic study in adults (abstract 605p). Ann Oncol 1996;7(suppl 5): 126.
44. Creemers G, Gerrits C, Eckardt J, Schellens JH, Burris HA, Planting HS, Rodriguez GI, Loos WJ, Hudson J, Broom C, Verweij J, Von Hoff D: Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to patients with solid tumors. J Clin Oncol 1996;15:1087-1093.
45. Johnson R, McCabe F, Yu Y: Combination regimens with topotecan in animal tumor models (abstract 107). Ann Oncol 1992;3(suppl 1): 85.
46. Rowinsky E, Kaufmann S, Baker S, Grochow L, Chen T-L, Peereboom D, Bowling M, Sartorius S, Ettinger D, Forastiere A, Donehower R: Sequences of topotecan and cisplatin: Phase I, pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14: 3074-3084.
47. Rothenberg M, Burris H III, Eckardt J, Rinaldi D, Weiss G, Smith S, Jones K, Johnson R, von Hoff D: Phase I/II study of topotecan + cisplatin in patients with non-small cell lung cancer (NSCLC) (abstract 423). Proc Am Soc Clin Oncol 1993;12:156.
48. Miller A, Lilenbaum R, Hollis D, Rosner G, Batist G, Bernhard S, Egorin M, Schilsky R, Ratain M: Pharmacologic study of continuous infusion topotecan and cisplatin in patients with advanced cancer: A Cancer and Leukemia Group B study (abstract 702). Proc Am Soc Clin Oncol 1997;16:200a.
49. Whitacre C, Zborowska E, Gordon N, Mackay W, Berger N: Topotecan increases topoisomerase II levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997;57:1425-1428.
50. Herben VM, ten Bokkel Huinink WW, Rodenhuis S, Schornagel J, Dubbelman R, Mandjes I, Beijnen J: Phase I and pharmacokinetic study of topotecan in combination with oral etoposide (abstract 472). Ann Oncol 1996;7(suppl): 133.
51. Crump M, Lipton J, Hedley D, Scott JG, Sutton D, Keating A, Minden M, Messner H, Eisenhauer E: A phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia (AML) (abstract 1050). Proc Am Soc Clin Oncol 1996;15:357.
52. Murren J, Anderson S, Fedele J, Pizzomo G, Belliveau D, Zelterman D, Burtness B, Tocino I, Flynn S, Beidler D, Cheng Y: dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J Clin Oncol 1997;15:148-157.
53. Miller CB, O'Reilly S, Sartorius S, Burke P, Kaufmann S, Donehower R, Rowinsky E, Grever M, Gore SD: A phase I and pharmacologic study of a combination of cyclophosphamide (CY) and topotecan (Topo) in patients (pts) with refractory leukemia (abstract 712). Proc Am Soc Clin Oncol 1997;16:203a.
54. Lilenbaum R, Ratain M, Miller A, Hargis J, Hollis D, Rosner G, O'Brian S, Brewster L, Green M, Schilsky R: Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study. J Clin Oncol 1995;13:2230-2237.
55. O'Reily S, Fleming G, Baker S, Walczak J, Bookman M, McGuire W, Schilder R, Alvarez R, Armstrong D, Horowitz I, Ozols R, Rowinsky E: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study. J Clin Oncol 1997;15:177-186.
56. Hochster H, Chachoua A, Sorich J, Wasserheit C, Taubes B, Friedberg A, Arbuck S, Speyer J: Phase I study of paclitaxel (P) combined with 14-day topotecan (T) continuous iv (CIV) infusion in previously treated and untreated patients (pts) (abstract 839). Proc Am Soc Clin Oncol 1997;16:238a.
57. Rowinsky E, Kaufmann S, Baker S, Miller C, Sartorius S, Bowling M, Chen T-L, Donehower R, Gore S: A phase I and pharmacological study of topotecan infused over 30 minutes for 5 days in patients with refractory acute leukemia. Clin Cancer Res 1996;2:1921-1930.
58. Kantijarian H, Beran M, Ellis A, Zweiling L, O'Brian S, Cazenave L, Koller Ch, Rios M, Plunkett W, Keating M, Estey E: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993;81:1146-1151.
59. Van Warmerdam L, Ten Bokkel Huinink W, Rodenhuis S, Koier I, Davies B, Rosing H, Maes R, Beijnen J: Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995;13:1768-1776.
60. Cooper BW, Lazarus HM, Creger R, Willson JKV, Hoppel CL, Berger SJ, Berger NA, Gosky DM, McGloin B, Gerson SL: A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL) (abstract 1549). Proc Am Soc Clin Oncol 1996;15: 486.
61. Miller A, Hargis J, Lilenbaum R, Fields S, Rosner G, Schilsky R: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study. J Clin Oncol 1994;12:2743-2750.
62. Eckardt J, Burris H III, Rinaldi D, Rodriguez G, Fields S, Smith S, Johnson R, von Hoff D: A phase I trial of the topoisomerase I inhibitor topotecan with cisplatin in patients with untreated non-small lung cancer (abstract 467). Ann Oncol 1994;5(suppl 5):192.
63. Hochster H, Chachoua A, Sorich J, Wasserheit C, Taubes B, Friedberg A, Arbuck S, Speyer J: Phase I study of paclitaxel (P) combined with 14-day topotecan (T) continuous infusion (CIV) in previously treated and untreated patients (PTS) (abstract 1131). Eur J Cancer 1997;33(suppl 8):250.
64. Herben VMM, Ten Bokkel Huinink WW, Dubbelman AC, Mandjes IAM, Groot Y, van Gortel-van Zomeren DM, Beijnen JH: Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997;76:1500-1508.
65. Schiller J, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D: Phase II study of topotecan in patients in extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1996;14: 2345-2352.
66. Ardizzioni A, Hansen H, Dombernofsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
67. Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK: Treatment of patients with small-cell-lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996;14:2785-2790.
68. Eckhardt J, Gralla R, Palmer MC, Gandara D, Laplante J, Sandler A, Fields SZ, Fitts D, Broom C: Topotecan as second-line therapy in patients with small-cell-lung cancer: A phase II study (abstract 513). Ann Oncol 1996;7(suppl 5):107.
69. Schiller JH, Von Pawel J, Clarke P, et al: Preliminary results of a randomized phase III trial of topotecan (T) versus CAV as second-line therapy of small-cell lung cancer (SCLC) (abstract 41). Lung Cancer 1997;18(suppl 1):13.
70. Manegold C, von Pawel J, Scheithauer W, Lan J, Schäfer B, Pastovic R, Staab H: Response of SCLC brain metastases on topotecan (SK&F 104864) therapy. Ann Oncol 1996;7(suppl 5): 106-107.
71. Jett JR, Day R, Levitt M, Wooley G, Jacobs S: Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy (abstract 38). Lung Cancer 1997;18(suppl 1).
72. Weitz JJ, Jung S-H, Marschke RF, Fitch TR, Jett JR: Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) trial (abstract 1053). Proc Am Soc Clin Oncol 1995;14:348.
73. Perez-Soler R, Fosella F, Glisson B, Lee J, Murphy W, Shin D, Kemp B, Lee J, Kane J, Robinson R, Lippman S, Kurie J, Huber M, Raber M, Hong W: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-513.
74. Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE: Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: No evidence of increased efficacy. Br J Cancer 1997;76:1636-1639.
75. Lynch TJJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:347-352.
76. Perez-Soler R, Khuri F, Pisters KM, Robinson R, Wimberly A, Lee JK, Fossella FV: Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy (abstract 1619). Proc Am Soc Clin Oncol 1997;16:450a.
77. Wiesenfeld M, Marks R, Grill J, Sloan J, Tazelaar H, Carroll T, Kugler J, Krook J: A randomized phase II study of topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol) with filgrastim in patients with advanced non-small cell lung cancer (abstract 1755). Proc Am Soc Clin Oncol 1997;16:488a.
78. Creemers G, Gerrits C, Schellens J, Planting A, van der Burg M, Beurden V, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996;14:2540-2545.
79. Hochster H, Ibrahim J, Liebes L, O'Dwyer P, Benson A III: Phase I study of 21-day topotecan continuous infusion for metastatic colorectal cancer (ECOG study 4293) (abstract 1032). Proc Am Soc Clin Oncol 1997;16:290a.
80. Sugarman SM, Ajani JA, Daugherty K, Winn R, Lanzotti V, Bearden JD, Abbruzzese JL: Aphase II trial of topotecan (TPT) for the treatment of advanced measurable colorectal cancer (abstract 686). Proc Am Soc Clin Oncol 1994; 13:225.
81. Rowinsky EK, Baker SD, Burks K, O'Reilly S, Donehower RC, Grochow LB: High-dose topotecan with colony-stimulating factor in fluoropyrimidine-refractory colorectal cancer. A phase II and pharmacodynamic study. Ann Oncol 1998;9:173-180.
82. Chang AY, Garrow G, Boros L, Asbury R. Pandya K, Keng P: Clinical and laboratory studies of topotecan in breast cancer (abstract 118). Proc Am Soc Clin Oncol 1995;14:105.
83. Goldschmidt E, Bonneterre J, Fumoleau P, Oberling F, Cupissol D, Misset JL: A phase II study of topotecan on a daily × 5 schedule as second line single agent therapy in patients with advanced breast cancer (abstract 598). Proc Am Soc Clin Oncol 1997;16:171a.
84. Spaeth D, Bonneterre J, Marty M, Khayat D, Faccini T, Conroy T: Phase II study of two regimens of topotecan as second-line single agent therapy in advanced breast cancer (abstract 675). Proc Am Soc Clin Oncol 1997;16:192a.
85. Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, McGuire W: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer (abstract 767). Proc Am Soc Clin Oncol 1995;14:274.
86. Creemers G, Bolis G, Gore M, Scarfone G, Lacave A, Guastalla J, Despax R, Favalli G, Kreinberg R, van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink W: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996;14:3056-3061.
87. Kudelka A, Tresukosol D, Edwards C, Freedman R, Levenback Ch, Chantarawiroj P, de Leon C, Kim E, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh J: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
88. Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, Chachoua A, Sorich J, Taubes B, Ludwig E, Broom C: Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of Topo-1 depletion (a NYGOG study) (abstract 326p). Ann Oncol 1996;7(suppl 5):69.
89. Gordon A, Bookman M, Malmstrom H, Bolis G, Mangioni C, Hall J, Carter J, Hudson I, Broom C: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel. International Topotecan Study Group Trial (abstract 763). Proc Am Soc Clin Oncol 1996;15:282.
90. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-486.
91. Ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarbelli C, Davidson N, Spanczynski M, Bolis G, Malström H, Coleman R, Fields S, Heron J-F: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian carcinoma. J Clin Oncol 1997;15:2183-2193.
92. Robert F, Soong S, Wheeler R: A phase II study of topotecan in patients with recurrent head and neck cancer. Am J Clin Oncol 1997;20: 298-302.
93. Sugarman SM, Pazdur R, Daugherty K, Evans D, Winn R, Dubovsky D, Goodwin JW, Abbruzzese JL: A phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer (abstract 684). Proc Am Soc Clin Oncol 1994;13:224.
94. Puc HS, Bajorin DF, Bosl GJ, Amsterdam A, Motzer RJ: Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 1995;13:163-165.
95. LawTM, Ilson DH, Motzer RJ: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 1995;12:143-145.
96. Kyritis A, Newlands ES, Borck CS, Gleason M, Jaeckle K, Levin V, Bower M, Evans H, Dane G, DeWitte M, Yung W: Phase II trial of topotecan as a continuous intravenous infusion (CIV) in patients with high-grade gliomas (abstract 1404). Proc Am Soc Clin Oncol 1997;16: 394a.
97. Giantonio BJ, Kosierowski R, Ramsey HE, Fox SC, McAleer CA, Roethke S, Ozols RF, Hudes GR: Phase II study of topotecan (TT) for hormone-refractory prostate cancer (HRPC) (abstract 774), Proc Am Soc Clin Oncol 1993;12:247.
98. Beran M, Kantarjian H, O'Brian S, Koller C, Al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese J, Andreeff M, Keating M, Estey E: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88:2473-2479.
99. Anzei H, Frost P, Abbruzzese JL: Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc Am Assoc Cancer Res 1992;33:340.